Today: 15 October 2025
Subscribe
NuScale’s Stock Skyrockets on 6GW SMR Deal – Is GE Vernova Missing Out?
 ·  ·  ·  · 

NuScale’s Stock Skyrockets on 6GW SMR Deal – Is GE Vernova Missing Out?

by
15 October 2025
  • NuScale SMR surges ~20%. NuScale Power’s ticker SMR jumped roughly 14% intraday on Oct. 13 and closed Oct. 15 around $55.09 – up 20.3% from the prior close [1] [2]. The rally was driven by a historic SMR contract: NuScale’s partner ENTRA1 inked a 6 GW deployment program with TVA (six 77-MWe NuScale reactors) – “the largest SMR deployment in U.S. history” [3] [4]. This 6GW plan (powering ~4.5 million homes and dozens of AI data centers) sent SMR stock soaring.
  • Huge market growth. The global small modular reactor market is booming – from $5.81 billion in 2024 to a projected $8.37 billion by 2032. Utilities and tech firms (Google, Microsoft, OpenAI, etc.) are backing SMRs for reliable 24/7 power. For example, TVA signed deals for SMRs from both NuScale (TVA/ENTRA1) and Kairos Power, and even reactivated stalled projects (like Clinch River) [5] [6]. Europe is reviving nuclear too: Italy is moving to restart reactors “including modular and advanced” designs [7], and GE Vernova/Samsung announced five BWRX-300 SMRs for Sweden [8].
  • NuScale tech edge. NuScale’s SMR is the first and only U.S. design certified by the NRC – initially a 50-MWe unit in 2020, uprated to 77 MWe in May 2025 [9] [10]. NuScale’s factory-built modules can be stacked (up to 12 per plant, ~924 MWe total) [11]. It has deep partnerships via ENTRA1 (financing and operating SMR plants), Standard Power (planning ~2 GW of SMRs for AI/data centers), and vendors like Paragon Energy (supply systems) [12] [13]. NuScale CEO John Hopkins calls the SMR “proven technology” that provides “clean, reliable, and, most importantly, safe” energy [14] [15]. Even Alphabet/Google’s CFO Ruth Porat has urged that “nuclear has to be a part of the mix” for future energy needs [16].
  • GE Vernova’s push. GE Vernova (GE’s nuclear arm, ticker GEV) is also racing to capture SMR demand with its BWRX-300 (300 MWe) reactor. In September, GE Vernova and Hitachi partnered with Samsung to sell BWRX-300s globally (five units proposed in Sweden) [17]. TVA has formally accepted GE Vernova’s SMR application at Clinch River [18], with more projects expected. YTD GE Vernova stock is up ~97% (versus +151% for SMR) [19]. However, GE Vernova’s legacy business faces headwinds: high tariffs and wind-unit costs are dragging profits [20]. This led Zacks to rate GEV a weaker pick (Zacks Rank “Sell”) compared to SMR (“Hold”) [21].

Analysts Weigh In

Analysts note that SMR’s recent rally reflects both real progress and speculative fervor. On one hand, NuScale’s NRC approvals and partnerships set it up as an industry leader [22] [23]. In early October, NuScale shares even spiked +5% when Italy’s government moved to reintroduce nuclear power with “modular” reactors [24] [25]. On the other hand, NuScale still loses money (burning ~$95M cash per quarter as of mid-2025) and faces stiff competition [26] [27]. The Zacks report notes NuScale has underperformed peers recently (SMR +12.7% in 3 months vs. GE Vernova +17.6%, NanoNuclear +35%) [28]. It warns that the energy market is competitive (especially with renewables) and that SMR’s valuation is stretched [29] [30].

Indeed, metrics show SMR’s stock is expensive: a forward price/sales ratio ~85× [31] (vs. ~4× for GEV [32]) and a Zacks Value Score of F [33]. Wall Street consensus reflects caution: out of ~15 analysts, most rate SMR a “Hold” or “Buy” with a median 12-month target around $37–$40 [34] – roughly 25–30% below today’s $55 price. TradingView’s aggregate target is similar (~$42.75) [35]. Zacks therefore assigns SMR a #3 (Hold) rating [36] and suggests waiting for a pullback. By contrast, GE Vernova (Zacks #4 Sell) is seen as cheaper (P/S ~4.4×) but burdened by $300–$400M in 2025 tariffs and wind costs [37].

Outlook

Looking ahead, the analysts and industry experts are mostly bullish on SMR demand but mixed on the stocks. The NuScale/ENTRA1/TVA 6 GW deal provides a concrete project to support NuScale’s outlook, and similar global initiatives are emerging (Poland, Romania, Sweden, etc.). Tech companies and utilities are planning data centers and industrial hubs powered by SMRs [38] [39]. “Utilities see SMRs as crucial to provide round-the-clock carbon-free power in the AI era,” notes an industry analysis [40]. NuScale plans its first plant by 2030 [41], and the U.S. government is funding many SMR projects, suggesting years of tailwinds.

However, execution risk remains high. Past SMR ventures have stumbled (NuScale’s 6-unit plant in Idaho was scrapped in 2023 after cost overruns [42]). Delays and budget increases could damp stock gains. In the short term, if SMR stock retreats toward analyst targets (~$37–$40), some buyers may step in – but a sustained rally would require continued positive news (e.g. contract awards, regulatory wins). In sum, NuScale appears to lead the SMR boom [43], but investors should weigh its lofty valuation. As financial strategist Marcin Frąckiewicz notes, “NuScale’s SMR tech breakthroughs and key partnerships give it an edge,” but caution is warranted given high expectations [44].

Sources: News and analysis from Zacks, NASDAQ, TS2.tech, Motley Fool, WPLN, and company releases [45] [46] [47] [48], stock quotes and data as of Oct. 14–15, 2025 [49] [50].

How it Works – the Micro Modular Nuclear Reactor
Watch this video on YouTube.

References

1. ts2.tech, 2. www.investing.com, 3. ts2.tech, 4. wpln.org, 5. wpln.org, 6. ts2.tech, 7. www.nasdaq.com, 8. www.nasdaq.com, 9. ts2.tech, 10. wpln.org, 11. ts2.tech, 12. ts2.tech, 13. ts2.tech, 14. ts2.tech, 15. ts2.tech, 16. ts2.tech, 17. www.nasdaq.com, 18. www.nasdaq.com, 19. www.nasdaq.com, 20. www.nasdaq.com, 21. www.nasdaq.com, 22. finviz.com, 23. ts2.tech, 24. www.nasdaq.com, 25. www.nasdaq.com, 26. www.nasdaq.com, 27. finviz.com, 28. finviz.com, 29. finviz.com, 30. finviz.com, 31. finviz.com, 32. www.nasdaq.com, 33. finviz.com, 34. ts2.tech, 35. ts2.tech, 36. finviz.com, 37. www.nasdaq.com, 38. ts2.tech, 39. ts2.tech, 40. ts2.tech, 41. ts2.tech, 42. wpln.org, 43. ts2.tech, 44. finviz.com, 45. finviz.com, 46. ts2.tech, 47. wpln.org, 48. ts2.tech, 49. ts2.tech, 50. www.investing.com

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

  1. Redwire (RDW) Shares Plummet on Shake-Up – Is a Takeoff Next?
  2. HOVR Stock Rockets as Horizon Aircraft Lands Pratt & Whitney Engine Partnership
  3. Rocket Lab (RKLB) Stock Blasts Off: Japan Launch Deals and Analyst Upgrades Fuel 700% Rally
  4. Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Related Articles

Canadian Solar (CSIQ) Stock Skyrockets: Analyst Upgrade & Battery Boom Ignite Rally
Previous Story

Canadian Solar (CSIQ) Stock Skyrockets: Analyst Upgrade & Battery Boom Ignite Rally

Quantum Rocket or Bubble? RGTI’s Stunning Surge Explained—And How It Stacks Up to IonQ, D‑Wave, and QUBT
Next Story

Rigetti Stock Skyrockets Amid Quantum Computing Boom – Bubble or Breakthrough?

Stock Market Today

  • BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%
    October 15, 2025, 3:36 PM EDT. Validea's guru fundamental report flags BRISTOL-MYERS SQUIBB CO (BMY) as the top pick among 22 strategies under the Partha Mohanram P/B Growth Investor model. The model looks for low book-to-market stocks with signs of durable growth, and BMY scores 88%, signaling strong interest from this approach. The stock is described as a large-cap Biotechnology & Drugs name. The scorecard notes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics mostly PASS, with R&D TO ASSETS and CAPEX TO ASSETS highlighted as favorable. Overall, the framework implies solid fundamentals and attractive valuation, with a high signal from the Mohanram growth criteria for investors tracking factor-based strategies.
  • Bristol-Myers Squibb (BMY) Rated 88% by Validea's Partha Mohanram P/B Growth Strategy
    October 15, 2025, 3:34 PM EDT. Validea's guru analysis for Bristol-Myers Squibb (BMY) shows BMY scoring highest among 22 guru strategies under the P/B Growth Investor model designed by Partha Mohanram. The model looks for low book-to-market stocks with signs of sustained growth; BMY, a large-cap growth stock in the Biotechnology & Drugs sector, earns an 88% rating based on fundamentals and valuation. An 80%+ score signals interest, while 90%+ indicates strong interest. The summary table shows many tests PASS (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, etc.), but notes a weakness for RESEARCH AND DEVELOPMENT TO ASSETS (FAILD). The report also provides background on Partha Mohanram and the concept of factor-based stock portfolios.
  • BMY Factor-Based Stock Analysis: Partha Mohanram's P/B Growth Model Rates Bristol-Myers Squibb at 88%
    October 15, 2025, 3:32 PM EDT. Validea's guru-based assessment ranks Bristol-Myers Squibb (BMY) highly under the Partha Mohanram P/B Growth Investor model. Of 22 guru strategies, BMY scores 88%, signaling notable interest from this growth framework. The model targets low book-to-market stocks with indicators of sustained future growth, and BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs sector. The report notes frequent PASS outcomes on key tests (BOOK/MARKET RATIO, ROA, CFO to assets, R&D to assets, etc.) and shows a favorable overall fundamental picture. An emphasis is placed on Mohanram's research on distinguishing winners among low book-to-market stocks, his academic role at the University of Toronto and his chair at the John H. Watson Chair in Value Investing.
  • Bristol-Myers Squibb Co (BMY) Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest
    October 15, 2025, 3:30 PM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) uses the P/B Growth Investor model from Partha Mohanram. The model seeks low book-to-market stocks with sustained growth. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs sector, and the rating is 88%, implying the strategy has interest (80%) and strong interest above 90%. The accompanying table shows key tests: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS all passing; R&D TO ASSETS is listed as FAIL. Overall, the framework flags favorable fundamentals and valuation for BMY, though the R&D-to-assets issue may merit closer scrutiny.
  • BMY Factor-Based Stock Analysis: Partha Mohanram's P/B Growth leads with 88%
    October 15, 2025, 3:28 PM EDT. Validea's guru analysis places BRISTOL-MYERS SQUIBB CO (BMY) at the top of its P/B Growth Investor model, a Partha Mohanram framework that seeks low book-to-market names with growth signals. Among 22 guru strategies tracked, BMY earns an 88% score under this model, signaling strong interest from growth-oriented screens. The table notes that key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW TO ASSETS, and R&D TO ASSETS show favorable results, while some metrics carry less weight within the strategy. As a large-cap biotech and drugs firm, BMY's fundamentals and valuation align with growth potential per Mohanram's research, though caveats apply to factor-based stock portfolios.
Go toTop